Tech Company Financing Transactions
Hillstar Bio Funding Round
On 3/25/2025, Hillstar Bio raised $67 million in Series A investment from Droia Ventures, Frazier Life Sciences and LifeArc.
Transaction Overview
Company Name
Announced On
3/25/2025
Transaction Type
Venture Equity
Amount
$67,000,000
Round
Series A
Proceeds Purpose
The company intends to use the funds to further enhance its lead program, which specifically targets TRBV9+ T cells, into clinical trials in 2026, and the expansion of its portfolio.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Boston, MA Undisclosed
USA
Boston, MA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
Hillstar Bio is bringing the next wave of precision immunotherapies to revolutionize autoimmune disease treatment. By selectively depleting pathogenic cells while preserving healthy ones, we aim to provide durable relief and drive an immune reset for patients with autoimmune conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Mabry
Browse more venture capital transactions:
Prev: 3/25/2025: ARK Capture Solutions venture capital transaction
Next: 3/25/2025: Navina venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries on this site come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs